Stabilization of vaccines and antibiotics in silk and eliminating the cold chain.

Tufts University, Department of Biomedical Engineering, Medford, MA 02155, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 07/2012; 109(30):11981-6. DOI: 10.1073/pnas.1206210109
Source: PubMed

ABSTRACT Sensitive biological compounds, such as vaccines and antibiotics, traditionally require a time-dependent "cold chain" to maximize therapeutic activity. This flawed process results in billions of dollars worth of viable drug loss during shipping and storage, and severely limits distribution to developing nations with limited infrastructure. To address these major limitations, we demonstrate self-standing silk protein biomaterial matrices capable of stabilizing labile vaccines and antibiotics, even at temperatures up to 60 °C over more than 6 months. Initial insight into the mechanistic basis for these findings is provided. Importantly, these findings suggest a transformative approach to the cold chain to revolutionize the way many labile therapeutic drugs are stored and utilized throughout the world.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Invasion of illness due to microbes has now becoming a worst situation for health associated professionals. As a fragile product, its storage and handling should be proper as recommended. Background: For the prevention and cure of diseases, vaccine has now become a popular tool biosafety. The main aim of the present study was to find out vaccines’ storage compartment temperature in different private clinics, hospitals, and community pharmacies in Karachi, Pakistan. The desired potency of vaccines is an integral part for vaccination. Result: During present study, visited 803 different clinics, centers, and pharmacies and found refrigerator and/or freezers only 491 clinics, centers, and pharmacies. In these 491, 107 private clinics, 9 governmental health care centers, 56 hospital, and 319 community pharmacies had been selected randomly because they kept vaccines. Only 77.19% were positively responds to our survey. The present study prevailed overall 38.52% and 7.32%, refrigerators and freezers had recommended temperature respectively in clinics, pharmacies, and health care centers. Conclusion: It has been found due to lack of knowledge, insufficient training, importance of cold chain, and above all shortage and/or breakdown of power supply have been played an important role. Based on the present study, it has been forcefully recommended there must be local guidelines or at least national guidelines. It has been tried to enhance the importance of cold chain for vaccines, and endeavor to implement the rules.
    International Journal of Pharmacy Teaching & Practices. 09/2014; 5(3):984.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We have used a protein-based vaccine, a live virus vaccine, and an experimental adjuvant to evaluate the utility of an advanced kinetic modeling approach for stability prediction. The modeling approach uses a systematic and simple procedure for the selection of the most appropriate kinetic equation to describe the degradation rate of compounds subjected to accelerated conditions. One-step and two-step reactions with unlimited combinations of kinetic models were screened for the three products under evaluation. The most appropriate mathematical model for a given product was chosen based on the values of residual sum of squares and the weight parameter w. A relatively simple n-th order kinetic model best fitted the degradation of an adjuvanted protein vaccine with a prediction error lower than 10%. A more complex two-step model was required to describe inactivation of a live virus vaccine under normal and elevated storage temperatures. Finally, an autocatalytic-type kinetic model best fitted the degradation of an oil-in-water adjuvant formulation. The modeling approach described here could be used for vaccine stability prediction, expiry date estimation, and formulation selection. To the best of our knowledge, this is the first report describing a global kinetic analysis of degradation of vaccine components with high prediction accuracy. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci
    Journal of Pharmaceutical Sciences 08/2014; · 3.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Global vaccination and gene therapy programs have an urgent demand for stabilization of viral vectors at low temperature. We used a quadramer, a bridge-connected DNA tetra-aptamer to antivesicular stomatitis virus (VSV), as a viral cryoprotectant. Results showed that the tetravalent antivirus DNA aptamers protect viral activity during multiple freeze− thaw cycles, shield from neutralizing antibodies, and decrease aggregation of viral particles. C ryoprotection of viral vectors is essential for the development of vaccines and anticancer therapeutics. Because of temperature sensitivity, many viruses should be stored frozen. 1 Therefore, delivery of active viruses depends on a cold chain, a distribution network set up to maintain optimal low temperatures during the transportation and storage. However, this cold chain system represents a major economic and logistical burden, estimated to be as high as 80% of the entire financial cost. 2 In addition, a viral vector should be infectious in the presence of a host's neutralizing antibodies (nAbs). In the work, we used vesicular stomatitis virus (VSV) as an important viral vector in targeted oncolytic immuno-therapies. 3 It is an enveloped RNA rhabdovirus that consists of a lipid envelope enclosing a nucleocapsid and an associated matrix formed by M proteins. 4−6 VSV is innocuous and engineered to target malignant cells and also increase a tumor's susceptibility to chemotherapeutic agents and the host immune response. Furthermore, VSV is a suitable choice for vaccine vectors and also has a key role in immunity and virology research. One of the challenges of utilizing VSV is its limited stability under different handling and storage conditions. 7
    ACS Medicinal Chemistry Letters 09/2014; 5(11). · 3.07 Impact Factor

Full-text (2 Sources)

Available from
May 23, 2014